Synchron

Synchron is developing a brain–computer interface (BCI) that is implanted through the blood vessels (endovascular) rather than via open-craniotomy placement of cortical arrays. Their core device concept is the Stentrode: a stent-mounted electrode array deployed into a cerebral venous sinus, paired with an implanted telemetry unit that transmits signals wirelessly.

This brief leans hard on peer‑reviewed clinical data and other primary sources.

Company background

• Website: ⁰¹
• Procedure (company description): Synchron describes a minimally-invasive endovascular procedure “similar to the placement of stents” that avoids open brain surgery. (Synchron homepage) ⁰¹
• Contact / location (company site footer): the site lists Brooklyn, NY along with contact emails. (Synchron contact/footer page) ⁰¹

Private-company note: revenue and profit figures for private neurotech startups are often unavailable or unverified. Funding figures are not revenue.

• Funding: Synchron announced a $200M Series D (reported as closed in Nov 2025) to accelerate commercialization of its first-generation Stentrode and a next-generation system. Source: ⁰²

The technology (what makes Synchron different)

1) Stentrode = stent‑electrode array in a blood vessel

A Stentrode is a stent-mounted electrode array permanently implanted into a blood vessel near cortex, enabling recording without penetrating brain tissue.

• Overview page (Wikipedia; includes citations to primary papers + trials): ⁰³

2) Implant location + signal path

Public descriptions and clinical papers describe:

• deployment via the jugular vein into a cerebral blood vessel adjacent to motor cortex,
• electrodes apposed to the vessel wall,
• signals routed to an implanted unit and sent wirelessly to an external receiver.

(Background overview and citations: Stentrode page) ⁰³

3) Why endovascular placement matters

Compared with intracortical arrays:

• Surgery burden may be lower (no craniotomy; uses interventional neurovascular techniques).
• Neural signal characteristics differ (electrodes are separated from cortex by vessel wall + CSF; recordings are typically closer to ECoG-like signals than penetrating microelectrode spikes).
• Vascular device risks are real (thrombosis/stenosis risk; need antiplatelet therapy considerations; imaging follow-up).

• Not verified here: a reported later Series E; wait for a primary Synchron announcement.

Human evidence (peer‑reviewed)

Safety in severe paralysis (JAMA Neurology, 2023)

A key human dataset is the SWITCH study (“Stentrode With Thought‑Controlled Digital Switch”). The publication reports safety outcomes in 4 patients with severe paralysis using a fully implanted endovascular BCI.

• Mitchell et al., JAMA Neurology (2023): “Assessment of Safety of a Fully Implanted Endovascular Brain‑Computer Interface for Severe Paralysis in 4 Patients: The Stentrode With Thought‑Controlled Digital Switch (SWITCH) Study.”
  • (DOI omitted; see PMC full text)
  • PMC full text: ⁰⁴

Earlier first‑in‑human experience (Journal of NeuroInterventional Surgery, 2020)

An earlier report describes first‑in‑human experience in severe paralysis and discusses activities-of-daily-living type outcomes.

• Oxley & Yoo, Journal of NeuroInterventional Surgery (2020): “Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: first in human experience.”
  • (DOI omitted; see PMC full text)
  • PMC: ⁰⁵

Preclinical foundation (Nature Biomedical Engineering, 2018)

The Stentrode concept was also demonstrated preclinically as a chronic endovascular interface.

• Opie et al., Nature Biomedical Engineering (2018): “Focal stimulation of the sheep motor cortex with a chronically implanted minimally invasive electrode array mounted on an endovascular stent.”
  • DOI: ⁰⁶

• Trials: a next-generation Stentrode study (FOCUS-AU) was scheduled to begin in Melbourne in April 2026. Source (Inside BCI, secondary): ⁰⁷

Trials (public registry)

ClinicalTrials.gov has entries relevant to early feasibility testing of the Stentrode device.

• “Stentrode with Thought-controlled Digital Switch…” (listed on the Stentrode overview page as NCT03834857) ⁰⁸

Company activity / “what they’re doing recently”

Synchron positions its BCI as an at‑home system aimed at autonomy and social connection.

• Company framing (Synchron homepage): ⁰¹

What to watch next (technical + translational)

1. Signal quality and bandwidth vs invasiveness

• Endovascular placement trades surgical invasiveness for potentially lower signal amplitude / spatial specificity compared with penetrating arrays.

2. Long-term vascular safety

• Chronic implant in cerebral venous sinuses raises questions about thrombosis risk, antiplatelet regimens, and long-term patency.

3. Decoder stability in real life

• The real benchmark is not “can you move a cursor once?” but stable daily use (months/years) with minimal retraining.

4. Expanding control modalities

• Today: cursor/OS control + discrete selections.
• Next: richer multi-DOF control, speech interfaces, or combined stimulation/recording applications.